WO2012124982A3 - Oral preparation having an enteric coating - Google Patents

Oral preparation having an enteric coating Download PDF

Info

Publication number
WO2012124982A3
WO2012124982A3 PCT/KR2012/001846 KR2012001846W WO2012124982A3 WO 2012124982 A3 WO2012124982 A3 WO 2012124982A3 KR 2012001846 W KR2012001846 W KR 2012001846W WO 2012124982 A3 WO2012124982 A3 WO 2012124982A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral preparation
enteric coating
relates
present
zoledronic acid
Prior art date
Application number
PCT/KR2012/001846
Other languages
French (fr)
Korean (ko)
Other versions
WO2012124982A2 (en
Inventor
이재걸
전호성
김진모
Original Assignee
현대약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 현대약품 주식회사 filed Critical 현대약품 주식회사
Publication of WO2012124982A2 publication Critical patent/WO2012124982A2/en
Publication of WO2012124982A3 publication Critical patent/WO2012124982A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an oral preparation containing zoledronic acid, which reduces enteric injuries and improves bioavailability. More particularly, the present invention relates to an oral preparation having an enteric coating, which comprises zoledronic acid and the pharmaceutically acceptable salts thereof, and which has a core, the pH level of which is 3.5 to 7.
PCT/KR2012/001846 2011-03-16 2012-03-14 Oral preparation having an enteric coating WO2012124982A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110023362A KR20120105738A (en) 2011-03-16 2011-03-16 An enteric-coated oral formulation
KR10-2011-0023362 2011-03-16

Publications (2)

Publication Number Publication Date
WO2012124982A2 WO2012124982A2 (en) 2012-09-20
WO2012124982A3 true WO2012124982A3 (en) 2012-11-08

Family

ID=46831213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001846 WO2012124982A2 (en) 2011-03-16 2012-03-14 Oral preparation having an enteric coating

Country Status (2)

Country Link
KR (1) KR20120105738A (en)
WO (1) WO2012124982A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362071A4 (en) * 2015-09-18 2019-07-17 Grünenthal GmbH Crystallization method and bioavailability

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009785A1 (en) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
WO2000061111A1 (en) * 1999-04-09 2000-10-19 Astrazeneca Ab A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
WO2001032185A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof
US6676965B1 (en) * 1999-10-20 2004-01-13 U&I Pharmaceuticals Ltd. Enteric coated formulation for bisphosphonic acids and salts thereof
US20050260262A1 (en) * 2004-05-24 2005-11-24 The Procter & Gamble Company Dosage forms of bisphosphonates
KR100631873B1 (en) * 2004-07-30 2006-10-09 주식회사 유유 Alendronic Acid Formulations with Enhanced Bioavailability
US20070134319A1 (en) * 2003-12-23 2007-06-14 Novartis Ag Pharmaceutical formulations of bisphosphonates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009785A1 (en) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
WO2000061111A1 (en) * 1999-04-09 2000-10-19 Astrazeneca Ab A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
US6676965B1 (en) * 1999-10-20 2004-01-13 U&I Pharmaceuticals Ltd. Enteric coated formulation for bisphosphonic acids and salts thereof
WO2001032185A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof
US20070134319A1 (en) * 2003-12-23 2007-06-14 Novartis Ag Pharmaceutical formulations of bisphosphonates
US20050260262A1 (en) * 2004-05-24 2005-11-24 The Procter & Gamble Company Dosage forms of bisphosphonates
KR100631873B1 (en) * 2004-07-30 2006-10-09 주식회사 유유 Alendronic Acid Formulations with Enhanced Bioavailability

Also Published As

Publication number Publication date
KR20120105738A (en) 2012-09-26
WO2012124982A2 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
WO2011012816A3 (en) Pharmaceutical formulation
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
EP2340821A4 (en) Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative of 5-aminolevulinic acid as active ingredient
WO2013082345A8 (en) Aryl dihydropyridinones and piperidinones as mgat2 inhibitors
WO2010092090A3 (en) Novel salts of sitagliptin
WO2014041565A3 (en) Improved process for preparation of vilanterol and intermediates thereof
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
WO2012056458A3 (en) Intermediate compounds and process for the preparation of fingolimod
WO2014064255A3 (en) Capsules
HRP20181437T1 (en) Method for the preparation of (3s,3s') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid)
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
WO2009117381A3 (en) Preparation of montelukast and its salts
ZA201107412B (en) Methods for the preparation of [2-8,9-dioxo2,6-diazabicyclo[5.2.0]non-1(1)-en-2-yl)ethyl]phosphonic acid and precursors thereof
WO2011058525A3 (en) Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2008049922A3 (en) A new process for the preparation of montelukast
UA106386C2 (en) Method for synthesizing ivabradine and the addition salts thereof with a pharmaceutically acceptable acid
WO2012112841A3 (en) [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation
WO2013017910A8 (en) Extended release pharmaceutical compositions containing paliperidone
WO2012074830A3 (en) Modified release tranexamic acid formulation
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
BRPI1012007A2 (en) "method for the preparation of 2-keto carboxylic acid"
WO2011136513A3 (en) Bone-transplant or bone-filling composition comprising a dihydroxybenzoic acid derivative
WO2010132390A3 (en) Method of decreasing ubiquitylated protein levels
IL225680A0 (en) Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12757638

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12757638

Country of ref document: EP

Kind code of ref document: A2